| |
|
|
|
|
|
 |
| |
|
¿¡½ºÄÚÆÇÁ¤ Escopan Tab.
|
|
ÀϹÝÀǾàǰ | ºñ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
645204230
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
Èò»ö¿øÇüÀÇ Çʸ§ÄÚÆÃÁ¤ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
10 Á¤/»óÀÚ(10Á¤/PTP) |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 15¹Ð¸®±×·¥ |
10 Á¤ |
º´ |
8806452042306 |
8806452042320 |
|
| 15¹Ð¸®±×·¥ |
10 Á¤ |
PTP |
8806452042306 |
8806452042313 |
|
|
| ÁÖ¼ººÐÄÚµå |
385300ATB
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
À§Åë,º¹Åë,»êÅë, À§»ê°ú´Ù,¼Ó¾²¸²
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
15¼¼ ÀÌ»ó ¼ºÀÎ : 1ȸ 2Á¤ 1ÀÏ 2~3ȸ ½ÄÈÄ ¶Ç´Â ½ÄÀü¿¡ º¹¿ëÇÑ´Ù.
´Ù¸¸, 1ÀÏ 2ȸ ÀÌ»ó º¹¿ë½Ã¿¡´Â 4½Ã°£ ÀÌ»óÀÇ °£°ÝÀ» µÎ°í º¹¿ëÇÑ´Ù.
|
| ±Ý±â |
1) ¸¸ 7¼¼ ÀÌÇÏÀÇ ¾î¸°ÀÌ
2) ÀÌ ¾àÀº À¯´çÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î, °¥¶ôÅä¿À½º ºÒ³»¼º(galactose intolerance), Lapp À¯´çºÐÇØÈ¿¼Ò °áÇÌÁõ(Lapp lactase deficiency) ¶Ç´Â Æ÷µµ´ç-°¥¶ôÅä¿À½º Èí¼öÀå¾Ö(glucose-galactose malabsorption) µîÀÇ À¯ÀüÀûÀÎ ¹®Á¦°¡ Àִ ȯÀÚ¿¡°Ô´Â Åõ¿©ÇÏ¸é ¾È µÈ´Ù.
|
| ½ÅÁßÅõ¿© |
´ÙÀ½°ú °°Àº »ç¶÷Àº ÀÌ ¾àÀ» º¹¿ëÇϱâ Àü¿¡ ÀÇ»ç, Ä¡°úÀÇ»ç, ¾à»ç¿Í »óÀÇÇÒ °Í.
1) ¾àÀ¸·Î ¾Ë·¹¸£±â Áõ»ó(¹ßÁø, ÃæÇ÷µÇ¾î ºÓ¾îÁü, °¡·Á¿ò µî)À» ÀÏÀ¸Å² ÀÏÀÌ ÀÖ´Â »ç¶÷
2) ½ÉÀåÀå¾Ö ȯÀÚ, ³ì³»Àå(´«ÀÇ ÅëÁõ, ´«ÀÇ Ä§Ä§ÇÔ µî) ¶Ç´Â ¹è´¢Àå¾Ö ȯÀÚ, Çã¾àÀÚ ¶Ç´Â °í·ÉÀÚ
3) ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ¿©¼º
4) ´Ù¸¥ ¾à¹°À» º¹¿ëÇϰí ÀÖ´Â »ç¶÷
|
| ÀÌ»ó¹ÝÀÀ |
´ÙÀ½°ú °°Àº »ç¶÷(°æ¿ì) ÀÌ ¾àÀÇ º¹¿ëÀ» Áï°¢ ÁßÁöÇϰí ÀÇ»ç, Ä¡°úÀÇ»ç, ¾à»ç¿Í »óÀÇÇÒ °Í. »ó´ã½Ã ÀÌ Ã·ºÎ¹®¼¸¦ ¼ÒÁöÇÒ °Í.
1) ÀÌ ¾àÀ» º¹¿ëÇÔÀ¸·Î½á ¾Ë·¹¸£±â Áõ»ó(¹ßÁø, °¡·Á¿ò µî)ÀÌ ³ªÅ¸³¯ °æ¿ì
2) ÀÌ ¾àÀ» º¹¿ëÇÔÀ¸·Î½á ±¸°¥, º¯ºñÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ¶Ç µÎÅë, ¾È¸éÈ«Á¶, ´«ºÎ½É, ¹è´¢Àå¾Ö µîÀÌ ³ªÅ¸³¯ °æ¿ì
3) ¿©·¯Â÷·Ê Åõ¿©ÇÏ¿©µµ Áõ»óÀÇ °³¼±ÀÌ ¾øÀ» °æ¿ì
|
| »óÈ£ÀÛ¿ë |
ÀÌ ¾àÀ» º¹¿ëÇÏ´Â µ¿¾È ´ÙÀ½ÀÇ ¾àÀ» º¹¿ëÇÏÁö ¸» °Í.
½ºÄÚÆú¸®¾Æ ¿¢½º ÇÔÀ¯ Á¦Á¦ ¹× ´Ù¸¥ À§ÀåÁøÅë¤ýÁø°æÁ¦
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
L-Menthol¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Dicyclomine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Action is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites and (2) a direct effect upon smooth muscle (musculotropic).
Papaverine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Perhaps by its direct vasodilating action on cerebral blood vessels, Papaverine increases cerebral blood flow and decreases cerebral vascular resistance in normal subjects; oxygen consumption is unaltered. These effects may explain the benefit reported from the drug in cerebral vascular encephalopathy.
|
| Pharmacology |
Dicyclomine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Dicyclomine is an anticholinergic drug, a medication that reduces the effect of acetylcholine, a chemical released from nerves that stimulates muscles, by blocking the receptors for acetylcholine on smooth muscle (a type of muscle). It also has a direct relaxing effect on smooth muscle. Dicyclomine is used to treat or prevent spasm in the muscles of the gastrointestinal tract in the irritable bowel syndrome. In addition, Dicyclomine inhibits gastrointestinal propulsive motility and decreases gastric acid secretion and controls excessive pharyngeal, tracheal and bronchial secretions.
Papaverine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is not paralyzed by Papaverine and still responds to drugs and other stimuli causing contraction. The antispasmodic effect is a direct one, and unrelated to muscle innervation. Papaverine is practically devoid of effects on the central nervous system. Papaverine relaxes the smooth musculature of the larger blood vessels, especially coronary, systemic peripheral, and pulmonary arteries.
|
| Metabolism |
Papaverine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Xanthine dehydrogenase/oxidase
|
| Protein Binding |
Dicyclomine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ >99%
Papaverine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ ~90%
|
| Half-life |
Dicyclomine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
Papaverine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 0.5-2 hours
|
| Absorption |
Dicyclomine¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
Papaverine¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
Ursodesoxycholic AcidÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- È¿°ú ¹ßÇö ½Ã±â : °æ±¸ : ´ã¼®¿ëÇØ : 3-6 °³¿ù
- Èí¼ö : °æ±¸ : 90% Èí¼ö
- ÃÊȸÅë°ú È¿°ú : 50-75 %
- ´Ü¹é°áÇÕ : 96-99 %
- ´ë»ç : Àå°£¼øÈ¯ : °£¿¡¼ glycine, taurineÀ¸·Î Æ÷ÇÕµÇ¸ç °£´ãµµ·Î ºÐºñµÈ´Ù.
Àå°üÀÇ ¼¼±ÕÃÑ¿¡ ÀÇÇØ Àç¼øÈ¯µÇ°Å³ª lithocholic acid·Î ÀüȯµÈ´Ù.
- ¼Ò½Ç : ´ëº¯¹è¼³ (lithocholic acid·Î ¹è¼³), ´¢¹è¼³ (°ÅÀÇ ¹è¼³µÇÁö ¾ÊÀ½)
°£¿¡¼ Æ÷ÇÕ, °£´ãµµ·Î ºÐºñµÈ ÈÄ¿¡ ´ã³¶¿¡ ³óÃàµÇ¾î ÀÖ´Ù°¡ À½½Ä¹° ¼·Ãë¿¡ ´ëÇÑ ½Åü¹ÝÀÀ¿¡ ÀÇÇØ ´ã³¶ÀÌ ¼öÃàµÇ¸é ´ãµµ¸¦ ÅëÇÏ¿© ½ÊÀÌÁöÀåÀ¸·Î ºÐºñµÈ´Ù.
- ¹Ý°¨±â : 100 ½Ã°£
L-mentholÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ¼Ò½Ç : Èí¼öµÈ ¾à¹°Àº glucuronide Æ÷ÇÕü·Î¼ ¼Òº¯ ¹× ´ãÁóÀ» ÅëÇØ ¹è¼³µÈ´Ù.
Papaverine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : °æ±¸ : ½Å¼Ó
- ´Ü¹é°áÇÕ : 90%
- ´ë»ç : °£¿¡¼ ½Å¼ÓÈ÷ ´ë»ç
- ¹Ý°¨±â : 0.5-1.5½Ã°£
- ¼Ò½Ç : ´¢¸¦ ÅëÇØ ÁÖ·Î ´ë»çü·Î ¹è¼³
Dicyclomine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : 1-2½Ã°£
- ÀÛ¿ëÁö¼Ó½Ã°£ : 4½Ã°£±îÁö
- Èí¼ö : °æ±¸ : Àß Èí¼öµÊ
- ºÐÆ÷ : Vd : 3.65 L/kg
- ´ë»ç : ´ë»ç Å
- ¹Ý°¨±â
- Ãʱ⠻ó(phase) : 1.8½Ã°£
- ¸»±â »ó : 9-10½Ã°£
- ¼Ò½Ç : ¹Ìº¯Èü·Î¼ ¼Ò·®¸¸ÀÌ ´¢¸¦ ÅëÇØ ¹è¼³µÊ
|
| Biotransformation |
Papaverine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Dicyclomine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
Papaverine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Dicyclomine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Donepezil Possible antagonism of actionGalantamine Possible antagonism of actionRivastigmine Possible antagonism of actionHaloperidol The anticholinergic increases the risk of psychosis and tardive dyskinesia
Papaverine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Probenecid Probenecid increases the antibiotic's level
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Dicyclomine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Take this medication 30 minutes before meals.
Papaverine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
|
| Drug Target |
[Drug Target]
|
| Description |
Dicyclomine¿¡ ´ëÇÑ Description Á¤º¸ A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms. [PubChem]
Papaverine¿¡ ´ëÇÑ Description Á¤º¸ An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels. [PubChem]
|
| Dosage Form |
Dicyclomine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralSolution IntramuscularSyrup OralTablet Oral
Papaverine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid Intravenous
|
| Drug Category |
Dicyclomine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anticholinergic AgentsAntimuscarinicsAntispasmodicsMuscarinic AntagonistsParasympatholytics
Papaverine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Phosphodiesterase InhibitorsVasodilator Agents
|
| Smiles String Canonical |
Dicyclomine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
Papaverine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
|
| Smiles String Isomeric |
Dicyclomine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
Papaverine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
|
| InChI Identifier |
Dicyclomine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3
Papaverine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3
|
| Chemical IUPAC Name |
Dicyclomine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate
Papaverine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-05-01
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|